Children need champions. Get involved, speak out, volunteer, or become a donor and give every child a fair chance to succeed.
Library Home | Reset filters
Select one or more filter options and click search below.
Reset filters
AUTHOR(S) Chloe A. Teasdale; Luisa N. Borrell; Yanhan Shen (et al.)
AUTHOR(S) Kaidi He; Wendy J. Mack; Michael Neely (et al.)
AUTHOR(S) Shamez N. Ladhani
AUTHOR(S) Bibhuti B. Das; Utkarsh Kohli; Preeti Ramachandran (et al.)
This research aims to characterize the clinical course and outcomes of children who developed probable myopericarditis after vaccination with the Pfizer- BioNTech (BNT162b2) COVID-19 mRNA vaccine. A cross-sectional study of 32 children, aged 12 through 18 years, diagnosed with probable myopericarditis following COVID-19 mRNA vaccination as per the CDC criteria for myopericarditis at 9 US centers between May 10, 2021 and June 20, 2021. We retrospectively collected the following data: demographics, SARS-CoV-2 virus detection or serologic testing, clinical manifestations, laboratory test results, imaging study results, treatment and time to resolutions of symptoms.
AUTHOR(S) Beate Kampmann; Uduak Okomo
AUTHOR(S) Adin Breuer; Allon Raphael; Hagay Stern (et al.)
This study evaluated the prevalence of paediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections using antibody testing and characterised antibody titres by time from exposure. This was a single-centre, prospective, cross-sectional cohort study. Patients under 18 years old were eligible to participate if they attended the paediatric emergency department at the tertiary Shaare Zedek Medical Center, Jerusalem, Israel, from 18 October 2020 to 12 January 2021 and required blood tests or intravenous access. SARS-CoV-2 seropositivity and antibody levels were tested by a dual-assay model.
AUTHOR(S) Kate Causey; Nancy Fullman; Reed J. D. Sorensen (et al.)
AUTHOR(S) S. Bookstein Peretz; N. Regev; L. Novick (et al.)
This study aims to determine the immunogenicity and reactogenicity of Pfizer's BNT162b2 COVID-19 vaccine among pregnant women compared with non-pregnant women, and to evaluate the obstetric outcome following vaccination. An observational case-control study of pregnant women, who were vaccinated by a 2-dose regimen of BNT162b2 vaccine during gestation between January-February 2021 (study group) and were compared to age-matched non-pregnant women who received the vaccine during the same time period (control group).
AUTHOR(S) Benjamin Fogel; Eric W. Schaefer; Steven D. Hicks
This investigation sought to determine whether early season rates of pediatric influenza vaccination changed in a season when there was a concurrent COVID-19 pandemic. This study used cohort and cross sectional data from an academic primary care division in Southcentral Pennsylvania that serves approximately 17,500 patients across 4 practice sites. Early season (prior to November 1) vaccination rates in 2018, 2019 and 2020 were recorded for children, age 6 months to 17 years.
AUTHOR(S) Kenneth J. Smith; Angela R. Wateska; Mary Patricia Nowalk (et al.)
AUTHOR(S) C. Sarai Racey; Robine Donken; Imogen Porter (et al.)
AUTHOR(S) Kristine M. Ruggiero; John Wong; Casey Fryer Sweeney (et al.)
With the COVID-19 vaccine rollout is well underway now beginning in children ages 12 and over, it is unknown what percent of parents plan to vaccinate their children against COVID-19. The purpose of this descriptive correlational study was to examine parents’ attitudes, beliefs, and behaviors in administering a COVID-19 vaccine.
AUTHOR(S) Lindsay A. Thompson; Sonja A. Rasmussen
Nearly 4 million children in the US have been infected with COVID-19 as of May 2021. While most children have had mild or no symptoms, thousands have been hospitalized and several hundred have died. Children with underlying conditions are more likely to experience severe effects of COVID-19, but even healthy children can be severely affected. Children can spread COVID-19 to others and also can have long-term effects that last months. For these reasons, children need to be protected from COVID-19. Currently, 3 vaccines are authorized for adults in the United States. In studies of tens of thousands of people, these vaccines were safe and effective. The vaccine made by Pfizer was recently authorized for children 12 years and older. Two doses of this vaccine are recommended to be given 3 weeks apart. The other 2 vaccines were authorized for persons 18 years and older but are expected to be available for teenagers soon. Studies in younger children as young as age 6 months are ongoing and if these studies show that they are safe and effective, vaccines could be available for children 6 months and older by late 2021 or early 2022.
AUTHOR(S) Gilbert G. G. Donders; Svitrigaile Grinceviciene; Kai Haldre (et al.)
AUTHOR(S) Simegnew Handebo; Maereg Wolde; Kegnie Shitu
Scientists across the world are working on innovating a successful vaccine that will save lives and end COVID-19 pandemic. World Health Organization (WHO) is working to make sure COVID-19 vaccines can be safely delivered to all those who need them. Indeed, the successful deployment and a sufficient uptake of vaccines is equally important. Acceptance and accessibility of such vaccine is a key indicator of vaccination coverage. This study aimed to assess the determinants of intention to receive COVID-19 vaccine among school teachers in Gondar City.
UNICEF Innocenti's Children and COVID-19 Library is a database collecting research from around the world on COVID-19 and its impacts on children and adolescents.
Read the latest quarterly digest on children and youth mental health under COVID-19.
Subscribe to updates on new research about COVID-19 & children
COVID-19 & Children: Rapid Research Response
